Critical Pharmacodynamic Warning
quinine affects the 3A457 metabolic pathway.
When patients take quinine concurrently with drugs metabolized by 3A457, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a under review, quinine can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for quinine
This page outlines known interaction pathways involving quinine, focusing primarily on its profile as a under review affecting the 3A457 pathway.
Enzyme Interaction Profile
quinine demonstrates under review potency against 3A457. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: quinine affects 3A457Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Known Inducers: barbituratesInteraction Details
| Drug Name | quinine |
| Affected Enzyme | 3A457 |
| Inhibitor Strength | under review Under Evaluation |
| Inducers | barbiturates |
| Inhibitors | amiodarone |
Clinical Recommendations
Clinical significance pending review. Exercise caution.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
331
3A457
Enzyme Inhibition
Under Evaluation
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 19, 2026